(COO) The Cooper Companies - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2166485019
Stock: Contact Lenses, Fertility Products, Medical Devices
Total Rating 49
Risk 91
Buy Signal -0.23
| Risk 5d forecast | |
|---|---|
| Volatility | 28.3% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.34 |
| Alpha | -23.94 |
| Character TTM | |
|---|---|
| Beta | 0.595 |
| Beta Downside | 0.160 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.17% |
| CAGR/Max DD | -0.18 |
EPS (Earnings per Share)
Revenue
Description: COO The Cooper Companies March 04, 2026
The Cooper Companies, Inc. (COO) operates in two segments: CooperVision and CooperSurgical. CooperVision develops and markets contact lenses correcting various vision impairments. CooperSurgical focuses on womens healthcare, offering fertility products, medical devices, contraception, and cryostorage services. This segment addresses a growing market for reproductive health solutions.
The company distributes its products through various channels, including distributors, group purchasing organizations, and healthcare professionals. The healthcare supplies sector is characterized by continuous innovation in medical devices and treatments. For a deeper understanding of COOs performance and market position, consider exploring its detailed financials and analyst reports on ValueRay.
Headlines to watch out for
- Contact lens sales drive CooperVision segment revenue
- Fertility product demand boosts CooperSurgical growth
- Regulatory changes impact medical device approvals
- Global economic downturn reduces elective healthcare spending
- Raw material costs affect contact lens manufacturing margins
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 401.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.81 > 1.0 |
| NWC/Revenue: 12.96% < 20% (prev 25.13%; Δ -12.17% < -1%) |
| CFO/TA 0.07 > 3% & CFO 866.4m > Net Income 401.4m |
| Net Debt (2.37b) to EBITDA (962.0m): 2.47 < 3 |
| Current Ratio: 1.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (196.7m) vs 12m ago -2.24% < -2% |
| Gross Margin: 64.24% > 18% (prev 0.67%; Δ 6.36k% > 0.5%) |
| Asset Turnover: 33.69% > 50% (prev 32.14%; Δ 1.55% > 0%) |
| Interest Coverage Ratio: 4.39 > 6 (EBITDA TTM 962.0m / Interest Expense TTM 105.5m) |
Altman Z'' 4.51
| A: 0.04 (Total Current Assets 2.13b - Total Current Liabilities 1.60b) / Total Assets 12.42b |
| B: 0.63 (Retained Earnings 7.77b / Total Assets 12.42b) |
| C: 0.04 (EBIT TTM 462.8m / Avg Total Assets 12.32b) |
| D: 1.84 (Book Value of Equity 7.46b / Total Liabilities 4.06b) |
| Altman-Z'' Score: 4.51 = AA |
Beneish M -2.95
| DSRI: 1.07 (Receivables 807.1m/716.4m, Revenue 4.15b/3.93b) |
| GMI: 1.04 (GM 64.24% / 67.00%) |
| AQI: 0.96 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 1.06 (Revenue 4.15b / 3.93b) |
| TATA: -0.04 (NI 401.4m - CFO 866.4m) / TA 12.42b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of COO shares?
As of March 23, 2026, the stock is trading at USD 69.96 with a total of 2,163,965 shares traded.
Over the past week, the price has changed by -1.52%, over one month by -15.65%, over three months by -16.56% and over the past year by -16.78%.
Over the past week, the price has changed by -1.52%, over one month by -15.65%, over three months by -16.56% and over the past year by -16.78%.
Is COO a buy, sell or hold?
The Cooper Companies has received a consensus analysts rating of 4.05.
Therefore, it is recommended to buy COO.
- StrongBuy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the COO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.3 | 30.4% |
| Analysts Target Price | 91.3 | 30.4% |
COO Fundamental Data Overview March 23, 2026
P/E Trailing = 34.806
P/E Forward = 15.5521
P/S = 3.2878
P/B = 1.6321
P/EG = 1.8247
Revenue TTM = 4.15b USD
EBIT TTM = 462.8m USD
EBITDA TTM = 962.0m USD
Long Term Debt = 1.88b USD (from longTermDebt, last quarter)
Short Term Debt = 620.7m USD (from shortTermDebt, last quarter)
Debt = 2.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.37b USD (from netDebt column, last quarter)
Enterprise Value = 16.03b USD (13.65b + Debt 2.50b - CCE 124.9m)
Interest Coverage Ratio = 4.39 (Ebit TTM 462.8m / Interest Expense TTM 105.5m)
EV/FCF = 32.62x (Enterprise Value 16.03b / FCF TTM 491.2m)
FCF Yield = 3.07% (FCF TTM 491.2m / Enterprise Value 16.03b)
FCF Margin = 11.83% (FCF TTM 491.2m / Revenue TTM 4.15b)
Net Margin = 9.67% (Net Income TTM 401.4m / Revenue TTM 4.15b)
Gross Margin = 64.24% ((Revenue TTM 4.15b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = 67.88% (prev 56.42%)
Tobins Q-Ratio = 1.29 (Enterprise Value 16.03b / Total Assets 12.42b)
Interest Expense / Debt = 0.90% (Interest Expense 22.4m / Debt 2.50b)
Taxrate = 31.95% (61.4m / 192.2m)
NOPAT = 315.0m (EBIT 462.8m * (1 - 31.95%))
Current Ratio = 1.34 (Total Current Assets 2.13b / Total Current Liabilities 1.60b)
Debt / Equity = 0.30 (Debt 2.50b / totalStockholderEquity, last quarter 8.36b)
Debt / EBITDA = 2.47 (Net Debt 2.37b / EBITDA 962.0m)
Debt / FCF = 4.83 (Net Debt 2.37b / FCF TTM 491.2m)
Total Stockholder Equity = 8.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.26% (Net Income 401.4m / Total Assets 12.42b)
RoE = 4.83% (Net Income TTM 401.4m / Total Stockholder Equity 8.31b)
RoCE = 4.54% (EBIT 462.8m / Capital Employed (Equity 8.31b + L.T.Debt 1.88b))
RoIC = 2.91% (NOPAT 315.0m / Invested Capital 10.83b)
WACC = 6.92% (E(13.65b)/V(16.15b) * Re(8.08%) + D(2.50b)/V(16.15b) * Rd(0.90%) * (1-Tc(0.32)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.10%
[DCF] Terminal Value 82.89% ; FCFF base≈448.6m ; Y1≈475.1m ; Y5≈564.4m
[DCF] Fair Price = 51.69 (EV 12.46b - Net Debt 2.37b = Equity 10.08b / Shares 195.1m; r=6.92% [WACC]; 5y FCF grow 6.53% → 2.90% )
EPS Correlation: -79.01 | EPS CAGR: -25.03% | SUE: 3.79 | # QB: 4
Revenue Correlation: 95.90 | Revenue CAGR: 5.77% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.10 | Chg7d=+0.030 | Chg30d=+0.030 | Revisions Net=+12 | Analysts=17
EPS current Year (2026-10-31): EPS=4.62 | Chg7d=+0.113 | Chg30d=+0.114 | Revisions Net=+18 | Growth EPS=+12.2% | Growth Revenue=+5.6%
EPS next Year (2027-10-31): EPS=5.02 | Chg7d=+0.072 | Chg30d=+0.063 | Revisions Net=+13 | Growth EPS=+8.6% | Growth Revenue=+5.2%
[Analyst] Revisions Ratio: +0.86 (13 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.2% (Discount Rate 8.1% - Earnings Yield 2.9%)
[Growth] Growth Spread = -0.1% (Analyst 5.1% - Implied 5.2%)
P/E Forward = 15.5521
P/S = 3.2878
P/B = 1.6321
P/EG = 1.8247
Revenue TTM = 4.15b USD
EBIT TTM = 462.8m USD
EBITDA TTM = 962.0m USD
Long Term Debt = 1.88b USD (from longTermDebt, last quarter)
Short Term Debt = 620.7m USD (from shortTermDebt, last quarter)
Debt = 2.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.37b USD (from netDebt column, last quarter)
Enterprise Value = 16.03b USD (13.65b + Debt 2.50b - CCE 124.9m)
Interest Coverage Ratio = 4.39 (Ebit TTM 462.8m / Interest Expense TTM 105.5m)
EV/FCF = 32.62x (Enterprise Value 16.03b / FCF TTM 491.2m)
FCF Yield = 3.07% (FCF TTM 491.2m / Enterprise Value 16.03b)
FCF Margin = 11.83% (FCF TTM 491.2m / Revenue TTM 4.15b)
Net Margin = 9.67% (Net Income TTM 401.4m / Revenue TTM 4.15b)
Gross Margin = 64.24% ((Revenue TTM 4.15b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = 67.88% (prev 56.42%)
Tobins Q-Ratio = 1.29 (Enterprise Value 16.03b / Total Assets 12.42b)
Interest Expense / Debt = 0.90% (Interest Expense 22.4m / Debt 2.50b)
Taxrate = 31.95% (61.4m / 192.2m)
NOPAT = 315.0m (EBIT 462.8m * (1 - 31.95%))
Current Ratio = 1.34 (Total Current Assets 2.13b / Total Current Liabilities 1.60b)
Debt / Equity = 0.30 (Debt 2.50b / totalStockholderEquity, last quarter 8.36b)
Debt / EBITDA = 2.47 (Net Debt 2.37b / EBITDA 962.0m)
Debt / FCF = 4.83 (Net Debt 2.37b / FCF TTM 491.2m)
Total Stockholder Equity = 8.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.26% (Net Income 401.4m / Total Assets 12.42b)
RoE = 4.83% (Net Income TTM 401.4m / Total Stockholder Equity 8.31b)
RoCE = 4.54% (EBIT 462.8m / Capital Employed (Equity 8.31b + L.T.Debt 1.88b))
RoIC = 2.91% (NOPAT 315.0m / Invested Capital 10.83b)
WACC = 6.92% (E(13.65b)/V(16.15b) * Re(8.08%) + D(2.50b)/V(16.15b) * Rd(0.90%) * (1-Tc(0.32)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.10%
[DCF] Terminal Value 82.89% ; FCFF base≈448.6m ; Y1≈475.1m ; Y5≈564.4m
[DCF] Fair Price = 51.69 (EV 12.46b - Net Debt 2.37b = Equity 10.08b / Shares 195.1m; r=6.92% [WACC]; 5y FCF grow 6.53% → 2.90% )
EPS Correlation: -79.01 | EPS CAGR: -25.03% | SUE: 3.79 | # QB: 4
Revenue Correlation: 95.90 | Revenue CAGR: 5.77% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.10 | Chg7d=+0.030 | Chg30d=+0.030 | Revisions Net=+12 | Analysts=17
EPS current Year (2026-10-31): EPS=4.62 | Chg7d=+0.113 | Chg30d=+0.114 | Revisions Net=+18 | Growth EPS=+12.2% | Growth Revenue=+5.6%
EPS next Year (2027-10-31): EPS=5.02 | Chg7d=+0.072 | Chg30d=+0.063 | Revisions Net=+13 | Growth EPS=+8.6% | Growth Revenue=+5.2%
[Analyst] Revisions Ratio: +0.86 (13 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.2% (Discount Rate 8.1% - Earnings Yield 2.9%)
[Growth] Growth Spread = -0.1% (Analyst 5.1% - Implied 5.2%)